Solar development taking hold in Kazakhstan FacebookTwitterLinkedInEmailPrint分享PV Magazine:JSC Kazakhstan Electricity and Power Market Operator (JSC KOREM) has revealed that the winner of the auction for a 50 MW solar power project in Kazakhstan’s Otyrar district is Italian oil and gas producer Eni.The group’s LLP Arm Wind unit offered the lowest price (not including VAT) of KZT 12.49 ($0.032)/kWh. “The ceiling auction price – KZT 29/kWh (excluding VAT) during the trading session decreased by 2.3 times,” JSC KOREM said.The 50 MW project is a joint initiative under the Ministry of Energy of the Republic of Kazakhstan, in cooperation with the UN Development Program. Eni is already active in the Kazakh energy market as a joint operator of the Karachaganak field. It is also an equity partner in various projects in the northern part of the Caspian Sea, including the giant Kashagan fieldThe auction has delivered a price which is lower by at least a third than those seen in the country’s first renewable energy auction in October 2018, when the final prices of the four selected PV projects, totaling 170 MW, ranged from KZT 18.6 to KZT 18.6.In another auction that was finalized in September, JSC KOREM selected a 10 MW PV project submitted by Russian developer Solnechnaya Sistema LLP, which offered a price of KZT 9.9/kWh, and a 26 MW solar project presented by KazSolar 50 LLP, which submitted a bid of KZT 16.97/kWh. The Solnechnaya Sistema LLP project will be built near the country’s Aral district, while the KazSolar 50 LLP plant will be built in the Shet district.Several more projects are being built outside the country’s auction scheme, including a 128 MW solar project by Total Eren and a 50 MW project by Suntech, among others. In January, German developer Goldbeck Solar said it had finished a 100 MW solar project near the town of Saran. That project also operates under a 15-year PPA, at a price of KZT34.61/kWh ($0.091). [Emiliano Bellini]More: Italy’s Eni wins Kazakhstan’s 50 MW solar auction with $0.032/kWh bid
Topics : “We’ll be prioritizing the vulnerable populations,” Varela said at the Mexican president’s daily news conference, noting that the pricing, while still not final, was not expected to exceed $4 per dose. That could bring the cost of the first 150 million doses to $600 million.Mexican President Andres Manuel Lopez Obrador hailed the agreement as “good news” for Mexico, and said the vaccine would be distributed without cost in the country, which ranks third worldwide in number of fatalities.Lopez Obrador said he expected the country to still be suffering from the pandemic by the time the vaccine goes into production.Argentina’s president flagged the agreement with Mexico and AstraZeneca, Britain’s second-largest drugmaker, on Wednesday, noting that the initial supply is meant to reach all Latin America except Brazil. Production of 400 million doses of a COVID-19 vaccine for Latin America could begin early next year, an executive for pharmaceutical company AstraZeneca Plc said on Thursday, as the region’s coronavirus death toll stands at nearly 230,000.In partnership with the Mexican and Argentinean governments, AstraZeneca plans to initially produce 150 million doses, and eventually make at least 400 million for distribution throughout the region, said Sylvia Varela, head of AstraZeneca Mexico.Home to some 650 million people, Latin America has registered the world’s highest tallies for coronavirus cases and deaths, with Brazil and Mexico trailing only the United States in record numbers of fatalities. Brazil earlier this month committed $355 million to purchase and produce the AstraZeneca vaccine.The Mexico-Argentina plan, whose cost is unclear, has significant funding from the foundation of Mexican billionaire Carlos Slim. A spokesman declined to give a sum.Varela said Phase III trials taking place in the United States, South Africa, England and Brazil were expected to conclude by November or December, after which the company would seek government approvals.If granted, the company would then transfer technology to Argentina’s INSUD Group and Mexico’s Laboratorios Liomont at the end of the year, and begin manufacturing in the first quarter of 2021, she said.The active substance in the vaccine would be made in Argentina and sent to Mexico to be completed for distribution, Varela said.